Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer

被引：0
|
作者：
Prince, Emily [1 ]
Pratt, James [2 ]
Novotny, James [2 ]
Chizhevsky, Vladislav [3 ]
Ragheb, Josette William [3 ]
Huron, David [2 ]
机构：
[1] Bristol Myers Squibb, Philadelphia, PA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] NeoGen Labs Inc, Aliso Viejo, CA USA
来源：
LABORATORY INVESTIGATION | 2020年 / 100卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
244
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [1] Analysis of Real-World PD-L1 Testing and PD-L1 IHC 28-8 and 22C3 Assay Concordance in Patients with Breast Cancer
    Prince, Emily
    Pratt, James
    Novotny, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 238 - 239
  • [2] Real-world PD-L1 test utilization and analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays in patients with breast cancer
    Mitra, Shreya
    Prince, Emily A.
    Pratt, James
    Novotny, James, Jr.
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    CANCER RESEARCH, 2021, 81 (04)
  • [3] A Comparative Study of PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx on Malignancies from the Lung
    Skov, Birgit
    Skov, Torsten
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S815 - S816
  • [4] Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types
    Krigsfeld, Gabriel S.
    Prince, Emily A.
    Pratt, James
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Novotny, James, Jr.
    Huron, David
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (10) : 656 - 664
  • [5] A Comparative Study of the PD-L1 IHC 22C3 and 28-8 Assays on Lung Cancer Samples
    Krigsfeld, G. S.
    Zerba, K.
    Novotny, J., Jr.
    Chizhevsky, V.
    Ragheb, J. W.
    White, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 236 - 237
  • [6] PD-L1 22C3 and 28-8 Expression in Malignant Mesotheliomas
    Stewart, Rachel
    Chapel, David B.
    Furtado, Larissa
    Husain, Aliya N.
    Krausz, Thomas
    Deftereos, Georgios
    LABORATORY INVESTIGATION, 2018, 98 : 751 - 751
  • [7] PD-L1 22C3 and 28-8 Expression in Malignant Mesotheliomas
    Stewart, Rachel
    Chapel, David B.
    Furtado, Larissa
    Husain, Aliya N.
    Krausz, Thomas
    Deftereos, Georgios
    MODERN PATHOLOGY, 2018, 31 : 751 - 751
  • [8] PD-L1 immunohistochemistry comparison of 22C3 and 28-8 assays for gastric cancer
    Narita, Yukiya
    Sasaki, Eiichi
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Kadowaki, Shigenori
    Ito, Seiji
    Yatabe, Yasushi
    Muro, Kei
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (06) : 2696 - +
  • [9] A comparative study of PD-L1 IHC 22C3 and 28-8 FDA-approved diagnostic assays in cancer
    Batenchuk, Cory
    Albitar, Maher
    Sudarsanam, Sucha
    Chizhevsky, Vladislav
    Jin, Chelsea
    Burns, Virginia A.
    CANCER RESEARCH, 2017, 77
  • [10] A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies
    Batenchuk, Cory
    Albitar, Maher
    Zerba, Kim
    Sudarsanam, Sucha
    Chizhevsky, Vladislav
    Jin, Chelsea
    Burns, Virginia
    JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (12) : 1078 - 1083
12345